2016, Volume 23, Supplement 1: Perspectives in chronic heart failure – new treatment advances

Introduction

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Introduction

Sameer Kurmani, Iain Squire

Abstract

Heart failure is a leading cause of morbidity and mortality and presents many treatment challenges. Its prognosis is poor yet many patients do not receive optimal therapy. In the UK, the increasingly ageing population means rates of heart failure hospitalisation are estimated to rise by 50% over the next 25 years....

| View
Neurohumoral activation in heart failure and the implications for treatment

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Neurohumoral activation in heart failure and the implications for treatment

Legate Philip, Paul R Kalra

Abstract

The pathophysiology of heart failure is complex. This article describes the neurohumoral pathways that are active in chronic heart failure with left ventricular systolic dysfunction (also known as heart failure with reduced ejection fraction [HFREF]). It also explains the rationale behind the development of therapies to favourably modulate the neurohumoral imbalance seen in this condition....

| View
Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

Pierpaolo Pellicori, Andrew L Clark

Abstract

PARADIGM-HF was the first study to compare the long-term efficacy and safety of the angiotensin-receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan (previously known as LCZ696), against standard care with the angiotensin-converting enzyme (ACE) inhibitor, enalapril, in patients with chronic symptomatic heart failure and reduced ejection fraction (HFREF). The trial was stopped early due to benefit....

| View
The use of sacubitril/valsartan (LCZ696) in clinical practice

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

The use of sacubitril/valsartan (LCZ696) in clinical practice

John McMurray

Abstract

Professor John McMurray, the principal investigator in the PARADIGM-HF study, writes about his experience with sacubitril/valsartan (known as LCZ696 at the time of the study) and how to optimally use this new agent in clinical practice, including how to switch patients to this treatment....

| View
A comment from primary care

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

A comment from primary care

Yassir Javaid

Abstract

Much of the work in reducing the mortality and morbidity from heart failure will be carried out in primary care. Treatment of these patients with optimal therapy will bring significant benefits. As the armamentarium of agents to treat this condition grows, this article considers why many patients are inappropriately treated in primary care and which patients will most benefit from the new angiotensin-receptor–neprilysin inhibitor (ARNI) class of drugs....

| View